RecruitingPhase 3NCT04217512
Pantoprazole in Cisplatin Nephrotoxicity
Possible Protective Effect of Pantoprazole in Cisplatin Induced Nephrotoxicity in Patients With Head and Neck Cancer
Sponsor
Sherief Abd-Elsalam
Enrollment
60 participants
Start Date
May 1, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
Pantoprazole in Cisplatin Nephrotoxicity
Eligibility
Inclusion Criteria1
- Patients with head and neck cancer
Exclusion Criteria3
- GFR less than 59.
- DM
- Elevated liver enzymes more than 3 fold.
Interventions
DRUGPantoprazole low dose
Pantoprazole 0.6 mg/kg
DRUGPantoprazole high dose
Pantoprazole 1.6 mg\\kg
OTHERStandard hydration
Standard hydration alone
DRUGCisplatin
Cisplatin
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04217512
Related Trials
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
NCT0407530518 locations
Curatively Intended Thoracic Reirradiation
NCT069500731 location
Breast Cancer and Chemobrain : Effects of Photobiomodulation on the Improvement of Perceived Cognitive Impairment
NCT069954431 location
Acceptability and Tolerance Study of Bolus Tube Feed With Food Blends
NCT073414642 locations
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
NCT066976004 locations